Compare · AXGN vs PXDT
AXGN vs PXDT
Side-by-side comparison of Axogen Inc. (AXGN) and Pixie Dust Technologies Inc. (PXDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and PXDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN carries a market cap of $2.09B.
- AXGN has hit the wire 6 times in the past 4 weeks while PXDT has been quiet.
- AXGN has more recent analyst coverage (11 ratings vs 0 for PXDT).
- Company
- Axogen Inc.
- Pixie Dust Technologies Inc.
- Price
- -
- -
- Market cap
- $2.09B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- News (4w)
- 6
- 0
- Recent ratings
- 11
- 0
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Latest AXGN
- Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
- BofA Securities initiated coverage on AxoGen with a new price target
- Barclays initiated coverage on AxoGen with a new price target
- Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
- Axogen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
- SEC Form 424B5 filed by Axogen Inc.
- Amendment: Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Latest PXDT
- SEC Form 6-K filed by Pixie Dust Technologies Inc.
- Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.
- Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.
- Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.
- Amendment: SEC Form SC 13D/A filed by Pixie Dust Technologies Inc.
- Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.
- SEC Form 25 filed by Pixie Dust Technologies Inc.
- /C O R R E C T I O N -- Pixie Dust Technologies/
- Amendment: SEC Form 6-K/A filed by Pixie Dust Technologies Inc.
- Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange Commission.